RedHill Biopharma Ltd. Sponsored ADR RDHL 深 沪
等待开盘 02-06 09:30:00 美东时间
1.01
-0.050
-4.72%
华盛通- 最 高1.09
- 今 开1.09
- 成交量 4.13万股
- 最 低 1.00
- 昨 收 1.06
- 总市值 231.45万
- 52周最高 5.75
- 市盈率 静 0.01
- 换手率 1.80%
- 52周最低 0.905
- 委 比 70.00%
- 总股本 229.16万
- 历史最高 22220.00
- 量 比 0.97
- 振 幅 8.49%
- 历史最低 0.905
- 每 手 1
- 风险率 1.04%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多What's Going On With Redhill Biopharma Stock On Tuesday?
RedHill Biopharma shares fell after a sharp rally as investors took profits, following updates on its GI drug aimed at easing GLP-1 treatment side effects and potential FDA approval paths.
01-06 23:26
RedHill Biopharma shares are trading higher after the company announced development progress for RHB-102.
RedHill Biopharma shares are trading higher after the company announced develop...
01-05 23:44
Market-Moving News for January 5th
ALT: 24% | Altimmune shares are trading higher after the FDA granted Breakthrough Therapy Designation for Pemvidutide in MASH. RDHL: 52% | RedHill Expands RHB-102 Clinical Development Addressing GLP-1
01-05 20:44
RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side Effects
RHB-1021 is a proprietary, advanced clinical-stage, once-daily, bimodal extended-release, oral tablet formulation of 5-HT3 antagonist, ondansetron, targeting oncology support, acute gastroen...
01-05 20:00
RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells
Resistance to venetoclax (Venclexta® and Venclyxto®, Abbvie / Genentech), the $2.5 billion blockbuster Chronic Lymphocytic Leukemia (CLL) therapy, is emerging as a therapeutic challenge, wit...
2025-12-15 20:00
RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement
TEL-AVIV, Israel and RALEIGH, N.C., Dec. 1, 2025 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced th...
2025-12-01 20:00
RedHill Biopharma Wins ~$10.5M Judgment Against Kukbo; RedHill Has Secured A Korean Court Attachment Grant Against Kukbo Aimed At Preventing Kukbo From Disposing Of Assets Prior To Judgment Enforcement
RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the New York Supreme Court's summary judgment in favor of RedHill against Kukbo Co. Ltd
2025-11-04 22:34
RedHill Biopharma Appeals Nasdaq Delisting Notice After Equity Boost
RedHill Biopharma ( ($RDHL) ) has provided an announcement. On October 16, 2025...
2025-10-23 05:17
RedHill receives Nasdaq staff determination notification
RedHill Biopharma (NASDAQ:RDHL) said it received a Nasdaq Staff Determination notice on October 16 stating the company failed to meet the minimum $2.5 million stockholders’ equity requirement for cont...
2025-10-23 04:54
RedHill Biopharma Receives Nasdaq Staff Determination Notification
On October 16, 2025, the Company received a Staff Determination notification from The Nasdaq Stock Market LLC regarding continued non-compliance with the minimum stockholders' equity require...
2025-10-23 04:50
